Brincidofovir_product_DataBase

Bioactivity

Brincidofovir (CMX001), the lipid-conjugated prodrug of Cidofovir (HY-17438), is an orally available, long-acting antiviral. Brincidofovir shows activity against a broad spectrum of DNA viruses including cytomegalovirus (CMV), adenovirus (ADV), varicella zoster virus, herpes simplex virus, polyomaviruses, papillomaviruses, poxviruses, and mixed double-stranded DNA virus infections. Brincidofovir, an oral antiviral in late stage development, has proven effective against orthopoxviruses in vitro and in vivo.[1][2][3][4].

Target

EC50: 5.5 nM (anti-CMV, in PDA at 7 dpi)

In Vivo

Brincidofovir (BCV) (20 mg/kg；口服；在第 1、3、5、7、10、14、17、21 和 24 天) 延长 IHD-J-Luc VACV 处理的免疫缺陷 BALB/c nu/nu 小鼠的存活期[3]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model:

CAS

444805-28-1

Formula

C27H52N3O7P

Molar Mass

561.69

Appearance

固体

Transport

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Reference

[1]. Hiwarkar P, et al. Brincidofovir is highly efficacious in controlling adenoviremia in pediatric recipients of hematopoietic cell transplant. Blood. 2017;129(14):2033-2037. [2]. Detweiler CJ, et al. Brincidofovir (CMX001) Toxicity Associated With Epithelial Apoptosis and Crypt Drop Out in a Hematopoietic Cell Transplant Patient: Challenges in Distinguishing Drug Toxicity From GVHD. J Pediatr Hematol Oncol. 2018;40(6):e364-e368. [3]. Zaitseva M, McCullough KT, Cruz S, et al. Postchallenge administration of brincidofovir protects healthy and immune-deficient mice reconstituted with limited numbers of T cells from lethal challenge with IHD-J-Luc vaccinia virus. J Virol. 2015;89(6):3295-3307. [4]. Scott A Foster , et al. The Role of Brincidofovir in Preparation for a Potential Smallpox Outbreak. Viruses. 2017 Oct 30;9(11):320.

PeptideDB

Brincidofovir

CAS: 444805-28-1 F: C27H52N3O7P W: 561.69